This review focuses on altered signaling pathways in schwannoma and identification of
molecular markers. Platelet derived growth factors PDGFR and ErbB family of receptor kinase are
overexpressed in the schwannoma. PDGFR-β inhibitors with a specific inhibitor AG1296 completely
inhibited both basal and PDGF mediated proliferation of human scwannoma cells. Sorafenib, a
PDGFR inhibitor currently applied for advanced renal cancer treatment also effectively reducing
tyrosine kinase activity and decreased cell proliferation in human schwannoma cells at low
concentration. This suggests that this drug could be a promising tool in the treatment of schwannoma.
Keywords: Human Schwannoma, Molecular Marker, Receptor Kinase, Sorafenib
